Joseph Zouein
Overview
Explore the profile of Joseph Zouein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
48
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zouein J, Naim N, Kourie H
Immunotherapy
. 2023 Jan;
15(2):93-100.
PMID: 36601860
Locoregional, as well as metastatic renal cell carcinoma, tends to relapse after nephrectomy or metastasectomy. Adjuvant therapy seems to be an effective strategy to reduce the risk of recurrence. All ...
12.
Kourie H, Succar B, Chouery E, Mehawej C, Ahmadieh N, Zouein J, et al.
BMC Med Genomics
. 2022 Oct;
15(1):217.
PMID: 36253817
Background: Bladder cancer (BC) is the 10 most frequent tumor worldwide. Evidence shows an association between elevated risk of BC and various single nucleotide polymorphisms (SNP). BC incidence was the...
13.
Kourie H, Ibnshamsah F, Zouein J, Naim N, Abbasi S, Allahloubi N, et al.
Future Oncol
. 2022 Jul;
18(24):2733-2744.
PMID: 35791837
Colorectal cancer (CRC) is ranked as the third most prevalent and the second deadliest cancer worldwide. In the Middle East and North Africa (MENA) region, the number of CRC cases...
14.
Zouein J, Haddad F, Eid R, Kourie H
Immunotherapy
. 2021 Dec;
14(2):155-167.
PMID: 34865502
Lung cancer is the second most common cancer worldwide and the leading cause of death among cancers. The progressive approvals of immunotherapy as first-line treatment options have helped improve cancer...
15.
Zouein J, Kesrouani C, Kourie H
Immunotherapy
. 2021 Jun;
13(12):1053-1065.
PMID: 34190579
PD-L1 is an important predictive biomarker for treatment by immune checkpoint inhibitors (ICIs). ICIs are now indicated for the treatment of various cancer depending on the level of expression of...
16.
Moujaess E, Khoury M, Zouein J, Bou Eid J, Mohty R, Kourie H
Future Oncol
. 2021 Jun;
17(22):2831-2834.
PMID: 34148366
The first 'advanced course on biomarkers in molecular and immuno-oncology' in the Middle East took place in Beirut, Lebanon, as a hybrid meeting on 11 December 2020. The aim of...
17.
Zouein J, Noujaim C, Kourie H
Biomark Med
. 2021 Jun;
15(9):609-613.
PMID: 34060324
No abstract available.
18.
Bitar L, Zouein J, Haddad F, Eid R, Kourie H
Biomark Med
. 2021 Jan;
15(2):135-138.
PMID: 33442995
Metastatic colorectal cancer is the second most common cause of cancer death. Standard chemotherapy in combination with targeted therapies represent the backbone for the treatment of advanced disease. However, options...